Point-of-Care Technologies for Precision Cardiovascular Care and Clinical Research

[1]  P. Collinson,et al.  High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study , 2015, The Lancet.

[2]  K. Rentsch,et al.  One-hour rule-in and rule-out of acute myocardial infarction using high-sensitivity cardiac troponin I. , 2016, American heart journal.

[3]  A. Jaffe,et al.  High-sensitivity cardiac troponin t concentrations below the limit of detection to exclude acute myocardial infarction: a prospective evaluation. , 2015, Clinical chemistry.

[4]  George M Whitesides,et al.  From the bench to the field in low-cost diagnostics: two case studies. , 2015, Angewandte Chemie.

[5]  Hakho Lee,et al.  Digital diffraction analysis enables low-cost molecular diagnostics on a smartphone , 2015, Proceedings of the National Academy of Sciences.

[6]  F. Apple,et al.  Cardiac troponin assays: a review of quantitative point-of-care devices and their efficacy in the diagnosis of myocardial infarction , 2015, Clinical chemistry and laboratory medicine.

[7]  K. Greaves,et al.  A novel diagnostic protocol to identify patients suitable for discharge after a single high-sensitivity troponin , 2015, Heart.

[8]  A. Rai,et al.  A smartphone dongle for diagnosis of infectious diseases at the point of care , 2015, Science Translational Medicine.

[9]  F. Ataullakhanov,et al.  Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk , 2015, Thrombosis Journal.

[10]  George M. Savage,et al.  An Ingestible Sensor for Measuring Medication Adherence , 2015, IEEE Transactions on Biomedical Engineering.

[11]  Jonathan W. Waks,et al.  Role of atrial fibrillation burden in assessing thromboembolic risk. , 2014, Circulation. Arrhythmia and electrophysiology.

[12]  S. Gutnikov,et al.  Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation–Related Embolic Vascular Events: A Population-Based Study , 2014, Circulation.

[13]  S. Bhatia,et al.  Disease Detection by Ultrasensitive Quantification of Microdosed Synthetic Urinary Biomarkers , 2014, Journal of the American Chemical Society.

[14]  Mortimer Poncz,et al.  T2 magnetic resonance: a diagnostic platform for studying integrated hemostasis in whole blood--proof of concept. , 2014, Clinical chemistry.

[15]  P. Loyalka,et al.  How do we manage cardiopulmonary bypass coagulopathy? , 2014, Transfusion.

[16]  Daniel Bernstein,et al.  Circulating Cell-Free DNA Enables Noninvasive Diagnosis of Heart Transplant Rejection , 2014, Science Translational Medicine.

[17]  G. Calin,et al.  Novel biomarkers for acute myocardial infarction: is microRNA the new kid on the block? , 2014, Clinical chemistry.

[18]  Hakho Lee,et al.  Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor , 2014, Nature Biotechnology.

[19]  Sanat S Bhole,et al.  Soft Microfluidic Assemblies of Sensors, Circuits, and Radios for the Skin , 2014, Science.

[20]  Gabriel A Kwong,et al.  Point-of-care diagnostics for noncommunicable diseases using synthetic urinary biomarkers and paper microfluidics , 2014, Proceedings of the National Academy of Sciences.

[21]  Douglas Losordo,et al.  Exosomes and cardiac repair after myocardial infarction. , 2014, Circulation research.

[22]  A. Shuldiner,et al.  Thrombin-induced platelet-fibrin clot strength: Relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes , 2013, Thrombosis and Haemostasis.

[23]  Kevin W Plaxco,et al.  Real-Time, Aptamer-Based Tracking of Circulating Therapeutic Agents in Living Animals , 2013, Science Translational Medicine.

[24]  N. Neff,et al.  Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy , 2013, Cell.

[25]  Fred S Apple,et al.  Diagnostic performance of four point of care cardiac troponin I assays to rule in and rule out acute myocardial infarction. , 2013, Clinical biochemistry.

[26]  J. Heit,et al.  Should platelet function testing guide antiplatelet therapy for patients with coronary artery stenting or acute coronary syndromes? , 2013, Clinical chemistry.

[27]  David K. Wood,et al.  Nanoparticles That Sense Thrombin Activity As Synthetic Urinary Biomarkers of Thrombosis , 2013, ACS nano.

[28]  Michelle L Rogers,et al.  Real-time clinical monitoring of biomolecules. , 2013, Annual review of analytical chemistry.

[29]  P. Donnan,et al.  Self-monitoring among non-insulin treated patients with type 2 diabetes mellitus: Patients' behavioural responses to readings and associations with glycaemic control. , 2013, Diabetes research and clinical practice.

[30]  M. Price,et al.  Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures , 2012, Thrombosis and Haemostasis.

[31]  C. Schindler,et al.  One-hour rule-out and rule-in of acute myocardial infarction using high-sensitivity cardiac troponin T. , 2012, Archives of internal medicine.

[32]  Akshay S. Desai,et al.  Rehospitalization for heart failure: predict or prevent? , 2012, Circulation.

[33]  I. Crozier,et al.  Modern device technologies. , 2012, Heart, lung & circulation.

[34]  Juan Carlos Souto,et al.  Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data , 2012, The Lancet.

[35]  S. Blankenberg,et al.  Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. , 2011, JAMA.

[36]  P. Teirstein,et al.  Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.

[37]  Raeed H. Chowdhury,et al.  Epidermal Electronics , 2011, Science.

[38]  Y. K. Cheung,et al.  1 Supplementary Information for : Microfluidics-based diagnostics of infectious diseases in the developing world , 2011 .

[39]  C. Israel,et al.  Fluid status monitoring with a wireless network to reduce cardiovascular-related hospitalizations and mortality in heart failure: rationale and design of the OptiLink HF Study (Optimization of Heart Failure Management using OptiVol Fluid Status Monitoring and CareLink) , 2011, European journal of heart failure.

[40]  S. Quake,et al.  Universal noninvasive detection of solid organ transplant rejection , 2011, Proceedings of the National Academy of Sciences.

[41]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[42]  Hakho Lee,et al.  Micro-NMR for Rapid Molecular Analysis of Human Tumor Samples , 2011, Science Translational Medicine.

[43]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[44]  Szilard Voros,et al.  Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients , 2011, BMC Medical Genomics.

[45]  H. Krumholz,et al.  Telemonitoring in patients with heart failure. , 2010, The New England journal of medicine.

[46]  A. Klein,et al.  The coagulopathy of cardiopulmonary bypass , 2010, Critical reviews in clinical laboratory sciences.

[47]  P. Zimetbaum,et al.  Ambulatory arrhythmia monitoring: choosing the right device. , 2010, Circulation.

[48]  Szilard Voros,et al.  Multicenter Validation of the Diagnostic Accuracy of a Blood-Based Gene Expression Test for Assessing Obstructive Coronary Artery Disease in Nondiabetic Patients , 2010, Annals of Internal Medicine.

[49]  Andrew St John,et al.  The Evidence to Support Point-of-Care Testing , 2010 .

[50]  Andrew St John,et al.  The value of self-monitoring of blood glucose: a review of recent evidence. , 2010, Journal of diabetes and its complications.

[51]  A. St John.  The Evidence to Support Point-of-Care Testing. , 2010, The Clinical biochemist. Reviews.

[52]  Christopher G Parkin,et al.  Value of Self-Monitoring Blood Glucose Pattern Analysis in Improving Diabetes Outcomes , 2009, Journal of diabetes science and technology.

[53]  B. Furie,et al.  Mechanisms of thrombus formation. , 2008, The New England journal of medicine.

[54]  Donhee Ham,et al.  Chip–NMR biosensor for detection and molecular analysis of cells , 2008, Nature Medicine.

[55]  J. Teerlink.  Learning the points of COMPASS-HF: assessing implantable hemodynamic monitoring in heart failure patients. , 2008, Journal of the American College of Cardiology.

[56]  M. Zile,et al.  Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. , 2008, Journal of the American College of Cardiology.

[57]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[58]  P. Libby,et al.  The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions , 2007, The Journal of experimental medicine.

[59]  W. Abraham,et al.  OptiVol® fluid status monitoring with an implantable cardiac device: a heart failure management system , 2007, Expert review of medical devices.

[60]  J. A. Armstrong.  Urinalysis in Western culture: a brief history. , 2007, Kidney international.

[61]  H. Krumholz,et al.  Telemonitoring for patients with chronic heart failure: a systematic review. , 2007, Journal of cardiac failure.

[62]  Samuel K Sia,et al.  Lab-on-a-chip devices for global health: past studies and future opportunities. , 2007, Lab on a chip.

[63]  G. Whitesides.  The origins and the future of microfluidics , 2006, Nature.

[64]  C. Chin,et al.  Lab-ona-chip devices for global health : Past studies and future opportunities , 2006 .

[65]  K. Reddy,et al.  Cardiovascular disease in non-Western countries. , 2004, The New England journal of medicine.

[66]  S. Quake,et al.  Microfluidic Large-Scale Integration , 2002, Science.

[67]  L. Rosenfeld.  Clinical chemistry since 1800: growth and development. , 2002, Clinical chemistry.

[68]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[69]  Deepak L. Bhatt,et al.  Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials , 2001, Circulation.

[70]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[71]  S. Quake,et al.  Monolithic microfabricated valves and pumps by multilayer soft lithography. , 2000, Science.

[72]  J. Manson,et al.  Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. , 1990, Circulation.

[73]  C. Goodman,et al.  Food and Drug Administration Center for Devices and Radiological Health , 1988 .

[74]  E. Braunwald,et al.  Circadian variation in the frequency of onset of acute myocardial infarction. , 1985, The New England journal of medicine.